Skip to main content

Generics

  • Aurobindo Pharma to open second U.S. plant

    HYDERABAD, India — Aurobindo Pharma said on Friday it plans to open a second U.S. plant for injectable products.

    According to the Hindustan Times, the announcement comes on the heels of President Trump calling on pharmaceutical companies to make more drugs locally. Aurobindo, India’s fourth-biggest drug maker by sales, earns more than half of its revenue in the United States.

  • CVS's Merlo: PBMs are the solution, not the problem

    WOONSOCKET, R.I. — One of CVS Health’s greatest challenges is to correct a misperception that pharmacy benefit managers are causing drug prices to rise, President and CEO Larry Merlo said Thursday during the company’s fiscal fourth-quarter earnings conference call.

  • Teva introduces Fusilev generic

    NORTH WALES, Pa. — Teva Pharmaceuticals announced the availability of its Levoleucovorin (Fusilev) generic for injection, used to treat toxic effects of methotrexate in people who have received methotrexate to treat bone cancer.

    Levoleucovorin is also used to treat or prevent toxic effects of methotextrate in people whose bodies do not eliminate methotextrate properly after the drug is metabolized. It can also be used to treat toxic effects of an accidental methotextrate overdose.

  • Healthcare system sees more than $1T in savings during past decade

    Generics have made a huge difference to the U.S. healthcare system’s bottom line in the past decade, a savings that takes 13 figures to tabulate.

    (To view the full Category Review, click here.)

  • Touting the benefits of generics: Q&A with GPhA’s Chip Davis

    Generics continue to grow as a proportion of the total prescriptions dispensed every year, and as that number has grown, so have the savings that generics bring to the healthcare system. The Generic Pharmaceutical Association has been front and center, touting the benefits that generics bring for lawmakers, payers and, most importantly, patients. Drug Store News spoke with GPhA president and CEO Chip Davis about the organization’s efforts in 2016 and plans for the remainder of 2017.

  • New final FDA guidance begins to clear path for more biosimilars

    As 2016 drew to a close, the Food and Drug Administration gave a gift of sorts to drug makers looking to submit to the agency an application for approval of a biosimilar drug when it issued its final guidance, “Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product.”

    (To view the full Category Review, click here.)

    The finalized guidance follows the draft guidance the agency issued in May 2014.

  • Camber introduces Fenofibrate generic

    PISCATAWAY, N.J. — Camber Pharmaceuticals launched Fenofibrate 48 and 145 mg tablets. The drug is the generic version of Tricor (Fenofibrate) tablets from Abbvie and is used to reduce cholesterol and triglycerides in the blood.

    Fenofibrate is available in 90ct bottles.

    Hetero Drugs, a large global player in developing, manufacturing and marketing of pharmaceuticals and their active ingredients, serves as parent company to Piscataway-based Camber Pharmaceuticals.

  • Global branded generics market expected to double by 2026

    VALLEY COTTAGE, N.Y. — The global branded generics market will more than double in value in just 10 years from a current $200 billion to $413.8 billion in 2016, according to a new report from Future Market Insights.

    The size of the global branded generics market is estimated to grow at a 7.3% compound annual growth rate for the 2016-2026 time period, FMI added.

X
This ad will auto-close in 10 seconds